Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > National Bank Comments

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Oct 25, 2023 7:25pm

67 Views

Post# 35701188

RE:RE:RE:RE:RE:RE:RE:RE:RE:National Bank Comments

Where did the Company mention a maximum offering of 25 million$ and the issue price per dhare?

SPCEO1 wrote:
It would be too costly
juniper88 wrote: Why renegotiate the terms with marathon again and again to just buy them out now??

palinc2000 wrote:
scarlet1967 wrote: Can anyone clarify why suddenly they need the funds?
When companies raise money they follow that up with intended use of funds! Not long ago the CFO said the low valuation was not justified, since then the layoffs now this without any explanation? Talking about poor communication...

Use of proceeds is not specified....
Maybe the proceeds will be used to get rid of Marathon